On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical study evaluating the investigational combination of islatravir and ...
We recently looked at Goldman Sachs’ Stocks With Highest Consensus Returns: 42 Stocks With The Highest Consensus ROE. In this ...
Zacks.com on MSN4d
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should KnowGilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some ...
TD Cowen analyst Tyler Van Buren has maintained their bullish stance on GILD stock, giving a Buy rating today. Tyler Van Buren’s rating ...
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
1d
Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...
Shares of Gilead Sciences Inc. GILD inched 0.33% higher to $84.95 Friday, on what proved to be an all-around great trading ...
We recently made a list of Goldman Sachs’ List Of Stocks Popular With Mutual Fund Managers: Top 20 Stocks. In this piece, we ...
Gilead Sciences is set to withdraw Trodelvy's accelerated approval for metastatic urothelial cancer following unsatisfactory ...
On Friday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $84.95 which represents a slight increase of $0.28 or 0.33% from the prior close of $84.67. The stock opened at $84 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback